Lantheus Holdings, Inc. LNTH
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Lantheus Holdings, Inc. is a U.S.-based radiopharmaceutical company focused on diagnostic imaging and targeted therapeutics for oncology, cardiology, and neurology applications. The company develops, manufactures, and commercializes radiopharmaceuticals and artificial intelligence-enabled imaging solutions used primarily in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) procedures. Lantheus operates within the broader healthcare, medical imaging, and nuclear medicine industries, with a strategic emphasis on precision diagnostics and theranostics. Its principal revenue drivers include prostate cancer imaging agent PYLARIFY, contrast agents, ultrasound enhancing agents, and nuclear imaging products used in hospitals, imaging centers, and physician practices.
Lantheus traces its origins to the medical imaging business historically associated with Bristol-Myers Squibb and later acquired by Avista Capital Partners before becoming publicly traded in 2015. The company has evolved from a traditional diagnostic imaging supplier into a radiopharmaceutical-focused enterprise centered on oncology imaging and targeted therapy development. Its strategic positioning has been strengthened through proprietary isotope supply arrangements, manufacturing capabilities, and commercialization infrastructure in nuclear medicine, particularly in prostate-specific membrane antigen (PSMA)-targeted imaging.
Business Operations
Lantheus generates revenue primarily through its Precision Diagnostics and radiopharmaceutical product portfolio. Major commercial products include PYLARIFY, a PSMA PET imaging agent for prostate cancer; DEFINITY, an ultrasound enhancing agent used in echocardiography; and legacy nuclear imaging products including TechneLite and Xenon-based diagnostic agents. The company also develops imaging analysis software and radiotherapeutic candidates through internal research and acquisitions. Revenue is derived from product sales, licensing arrangements, and strategic collaborations with healthcare providers, pharmaceutical firms, and imaging networks.
The company operates principally in the United States, while also maintaining selective international activities through partnerships and distribution relationships. Lantheus controls specialized radiopharmaceutical manufacturing and distribution infrastructure due to the short half-life and handling requirements of nuclear isotopes. Key strategic relationships include isotope supply agreements and collaborations with pharmaceutical and imaging companies. Notable subsidiaries and acquired assets include Progenics Pharmaceuticals, which expanded Lantheus’s oncology imaging pipeline, and investments tied to radiotherapeutic development and PET imaging technologies.
Strategic Position & Investments
Lantheus has prioritized growth through expansion in precision oncology imaging and theranostics. The commercial success of PYLARIFY significantly increased the company’s exposure to the prostate cancer imaging market, positioning it among leading PSMA-focused imaging providers in the United States. Strategic investments have included radiopharmaceutical manufacturing capacity, isotope access agreements, and development-stage therapeutic programs targeting cancer diagnostics and treatment combinations. The company has also invested in AI-enabled imaging analytics and next-generation radiopharmaceutical technologies intended to support personalized medicine initiatives.
A major strategic milestone was the acquisition of Progenics Pharmaceuticals in 2020, which expanded Lantheus’s oncology portfolio and intellectual property base. The company has also pursued investments and partnerships in alpha-emitting and beta-emitting therapeutic technologies, reflecting broader industry movement toward integrated diagnostic and therapeutic radiopharmaceutical platforms. Lantheus has publicly emphasized disciplined capital allocation, targeted acquisitions, and expansion of its precision medicine capabilities as central components of its long-term strategy.
Geographic Footprint
Lantheus is headquartered in Bedford, Massachusetts, and maintains operations primarily across North America, with commercial reach extending into selected international markets through distribution agreements and strategic partnerships. Its radiopharmaceutical manufacturing and logistics infrastructure is concentrated in the United States due to regulatory, isotope handling, and time-sensitive delivery requirements associated with nuclear medicine products.
The company’s products are used in healthcare systems and imaging centers across the United States, while certain diagnostic agents and technologies have market presence in parts of Europe, Canada, and other international regions through licensing or distribution channels. Lantheus’s operational influence is strongest in U.S. oncology imaging, though its investment activity and strategic partnerships reflect participation in the broader global radiopharmaceutical and precision diagnostics market.
Leadership & Governance
Lantheus is led by executives with backgrounds in pharmaceuticals, medical imaging, biotechnology, and healthcare commercialization. The company’s leadership strategy has emphasized expanding high-growth oncology imaging assets while maintaining stable cash flow from established diagnostic imaging products. Corporate governance is overseen by a board of directors with experience in healthcare operations, biotechnology investment, and regulated medical product commercialization.
Key executives include:
- Brian Markison – Chairman of the Board
- Brian Markison – Interim Chief Executive Officer
- Robert J. Marshall – Chief Financial Officer
- Mary Anne Heino – Former President and Chief Executive Officer
- Paul Blanchfield – Chief Operating Officer
- Ryan Schloth – Chief Legal Officer and Corporate Secretary
- Shazad Malik – Chief Medical Officer
Publicly available filings and company disclosures indicate that management’s strategic vision centers on building Lantheus into a leading radiopharmaceutical and precision diagnostics platform, with continued emphasis on oncology imaging, theranostics, manufacturing scale, and targeted acquisitions. Some executive role transitions and interim appointments have changed over recent reporting periods; data regarding certain leadership changes may vary across public sources depending on filing dates and announcement timing.